4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
Fifteen patients with advanced epithelial ovarian cancer were treated with 4-demethoxydaunorubicin (IMI-30) after platinum failure. A total of 33 courses of IMI-30 15 mg/m2, per os, daily for 3 consecutive days every 3 weeks were performed. Three patients experienced severe hematologic toxicity (WHO grade greater than or equal to 3), while gastroenteric toxicity was acceptable and no cardiotoxicity was observed. One minor response, 4 stabilization of disease and 7 progression were observed in 12 evaluable patients. In conclusion, IMI-30, at this scheduling, is inactive in our small series of heavily pretreated epithelial ovarian cancer patients.
Bruzzone
M
M
Chiara
S
S
Falcone
A
A
Graziani
G
G
Conte
P F
PF
Rosso
R
R
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015255:Idarubicin; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D015255:Idarubicin; D003630:Daunorubicin